BridgeBio Oncology Therapeutics BBOT
NASDAQ BBOT
$3.94 -0.16 (-3.90%)
At close: Oct 1, 2026 · 4:00 PM EDT

BridgeBio Oncology Therapeutics (BBOT) Non-Current Deffered Revenue (2024 - 2025)

Updated

BridgeBio Oncology Therapeutics (BBOT) recorded Non-Current Deffered Revenue of $5.52 million in Q2 2025, unchanged from $5.52 million a year earlier and unchanged from the prior quarter.

Analysis

BridgeBio Oncology Therapeutics (BBOT) Non-Current Deffered Revenue (2024 - 2025) Analysis & Trends

Starting with Q2 2024, BridgeBio Oncology Therapeutics' Non-Current Deffered Revenue history includes 5 quarters.

  • Per Business Quant, the preceding three quarters came in at $5.52 million (Q1 2025), $5.52 million (Q4 2024) and $5.52 million (Q3 2024).
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non-Current Deffered Revenue (Qtr)
1 Johnson & Johnson 638.12 Bn 556.64 Bn 17.26 Bn -
2 AbbVie 462.60 Bn 435.75 Bn 12.70 Bn -
3 Merck 358.70 Bn 313.13 Bn 12.21 Bn -
4 Novartis Ag 272.16 Bn 228.03 Bn 11.24 Bn -
5 Astrazeneca 250.36 Bn 223.92 Bn 12.86 Bn -
6 Amgen 227.87 Bn 183.27 Bn 7.24 Bn -
7 Gilead Sciences 184.97 Bn 159.08 Bn 6.22 Bn -
8 Pfizer 162.61 Bn 109.56 Bn 10.94 Bn -
9 Vertex Pharmaceuticals 132.45 Bn 104.46 Bn 2.84 Bn -
10 BridgeBio Oncology Therapeutics 328.47 Mn -1.04 Bn - -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2025 5.52 Mn
Mar 31, 2025 5.52 Mn
Dec 31, 2024 5.52 Mn
Sep 30, 2024 5.52 Mn
Jun 30, 2024 5.52 Mn
API Access

BridgeBio Oncology Therapeutics Non-Current Deffered Revenue API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=non-current-deffered-revenue&ticker=BBOT&period=max&api_key=YOUR_API_KEY